Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. Show more
Location: 601 Brickell Key Drive, Miami, FL, 33131, United States | Website: https://www.smmttx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
15.3B
52 Wk Range
$6.78 - $36.91
Previous Close
$20.60
Open
$20.79
Volume
2,136,418
Day Range
$20.32 - $21.31
Enterprise Value
14.94B
Cash
361.3M
Avg Qtr Burn
-43.29M
Insider Ownership
84.32%
Institutional Own.
13.52%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC | BLA Submission | |
Ivonescimab (SMT112) Details 1L Non-small cell lung carcinoma | BLA Submission | |
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC | BLA Submission | |
Ivonescimab Details 1L PD-L1 positive Non-small cell lung carcinoma | Phase 3 Data readout | |
Ivonescimab Details PD-L1 positive NSCLC | Phase 3 Update | |
Ivonescimab (SMT112) +Chemotherapy Details Biliary Tract Cancer | Phase 2 Update | |
Ridinilazole Details Intestinal infection, Bacterial infection | Failed Discontinued |